Clinical near-term Lead NAMPT inhibitor program RPT1G progressing to the clinic in 2024 with first-in-human data from healthy volunteers, presenting a near-term entry point for partnerships or collaboration on biomarker-driven oncology and metabolic disease trials.

Strategic financing Recent $18M financing and active fundraising signals provide a window for co-development or strategic investments with biotech funders and potential pharma partners seeking early-stage NAMPT inhibitors and tunable efficacy profiles.

Hematologic focus Emphasis on hematologic malignancies alongside solid tumors offers sales opportunities with hematology-oncology product teams, CROs, and service providers supporting translational and early-phase trial activities.

Tolerability edge Unique hyperbolic NAMPT inhibition with tunable on-target toxicity suggests a competitive differentiator for partnering to explore combination regimens, biomarkers, and safety-focused trial designs.

Industry visibility Active presence at major conferences (AACR 2026) and ongoing leadership hiring indicate growth and collaboration readiness, creating opportunities for co-promotion, licensing discussions, and academic-industrial partnerships.